Early day motion tabled by primary sponsor Mary Glindon (Labour), on Monday, 18 April 2016, in the House of Commons. It is signed by 28 members in total.

---

APPROVAL FOR DUCHENNE MUSCULAR DYSTROPHY TREATMENT, TRANSLARNA

That this House welcomes the decision by the National Institute for Health and Care Excellence (NICE) to recommend the Duchenne muscular dystrophy treatment, Translarna, for funding by NHS England, as a result of a Managed Access Agreement; notes that Translarna is the first ever approved drug to treat an underlying genetic cause of Duchenne muscular dystrophy; recognises the tireless campaigning by patients and families throughout the NHS England and NICE processes calling for access to Translarna; acknowledges the vital role that Muscular Dystrophy UK and Action Duchenne have played as patient organisation stakeholders during the NICE assessment process; further recognises the role of other charities in pressing for access to Translarna; further notes with concern the announcement by the Scottish Medicines Consortium to recommend that Translarna not be approved for funding by NHS Scotland; and calls on NHS England to shorten implementation from three months so that the drug is available as quickly as possible.

---

Secondary information

Type

Early day motion

Reference

1382 

Session

2015-16

Other sponsors

Peter Bottomley

Jim Cunningham

Mark Durkan

Baroness Ritchie of Downpatrick

Jim Shannon

Subjects

Health services Diseases

Link

View this Early day motion on www.parliament.uk